Live Breaking News & Updates on Immuno Oncology

Stay updated with breaking news from Immuno oncology. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

AIM ImmunoTech Announces First Dose Level is Generally

Next safety cohort to begin escalated dosing soon. ....

United States , Investigators At Erasmus Medical Center , Immunotech Inc , Erasmus Medical Center , Response Evaluation Criteria , Solid Tumors , Nyse Aim , Aim Immunotech Inc , Immuno Oncology , Pancreatic Cancer ,

Compare humanized mouse models

The Jackson Laboratory provides a model comparison guide for its line of humanized mouse models ....

Jackson Laboratory , Product Brochure , Immuno Oncology , Humanized Mouse Models , Ene Expression , Animal Models ,

Toripalimab Plus Axitinib Approved in China for Frontline Renal Cell Carcinoma

The NMPA of China has approved toripalimab plus axitinib for use in the first-line treatment of patients with medium- to high-risk unresectable or metastatic RCC. ....

Jun Guo , National Medical Products Administration Of China , Shanghai Junshi Biosciences Co Ltd , University Cancer Hospital , International Metastatic Renal Cell Carcinoma Database Consortium , National Medical Products Administration , Peking University Cancer Hospital , Global Oncology , Immuno Oncology , Genitourinary Cancers , Toripalimab Plus Axitinib , First Line Treatment Of Patients With Medium To High Risk Unresectable Or Metastatic Rcc , The National Medical Products Administration Of China ,

Perioperative Pembrolizumab Wins Approval in Europe for Resectable NSCLC at High Risk of Recurrence

The European Commission has approved neoadjuvant pembrolizumab plus chemotherapy, followed by adjuvant pembrolizumab, for high-risk, resectable NSCLC. ....

United States , Merck Keytruda , Solange Peters , American Joint Committee On Cancer Staging Manual , Centre Hospitalier Universitaire Vaudois , European Commission , American Joint Committee , Cancer Staging , Immuno Oncology , Lung Cancer , Global Oncology , The European Commission , Neoadjuvant Pembrolizumab Plus Chemotherapy , Ollowed By Adjuvant Pembrolizumab , High Risk , Resectable Nsclc ,

AIM ImmunoTech to Present at the MedInvest Biotech & Pharma

Live webcast presentation on Wednesday, April 3rd at 1:35 PM ET. ....

New York , United States , Thomask Equels , Immunotech Inc , Chief Executive Officer , Medinvest Biotech , Pharma Investor Conference , Nyse Aim , Aim Immunotech Inc , Immuno Oncology , Breast Cancer , Pancreatic Cancer , Ovarian Cancer , Covid 19 , Long Covid ,